Enhancing the Solubility of BCS Class IV Antibiotics to Unleash Their Potential
Source abstract
Abstract
Water solubility is a key physicochemical property during drug development, yet about 90% of new drug candidates exhibit low solubility. Numerous approaches have been proposed to enhance drug solubility, including physical modification and the use of solubilizing agents, formulation modifications, and nanotechnology techniques. Increasing both the solubility and dissolution rate of the drug substance is an important element of drug formulation technology, aimed at improving therapeutic efficacy and bringing economic benefits—both in the production process and by reducing the cost of therapy for the patient. Moreover, enhancing solubility helps reduce dosing, which is key to combating antibiotic overuse and resistance. This article reviews the newest methods and effects for increasing solubility and the dissolution rate of antibacterial substances in biopharmaceutics classification system (BCS) class IV, characterized by low water solubility and limited intestinal permeability. Particular attention was paid to summarizing the newest strategies to guide future formulation development and critically evaluate the literature.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Drug Solubulity and Delivery Systems · Silymarin and Mushroom Poisoning · Antibiotics Pharmacokinetics and Efficacy
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Doctoral School of Medicinal and Health Sciences, Jagiellonian University Medical College, Św. Łazarza 16, 31-530 Kraków, Poland
Chair of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland
Funding
Jagiellonian University—Medical College
References (99)
Show source-provided references
1. Enhancement of Solubility BCS Class II and IV Pharmaceuticals by Liqusolid Technique: A Review10.24198/idjp.v2i2.27297 ↗
2. Novel Approaches to Enhance Solubility Medicine: Pharmaceutical Sciences—Industrial Pharmacy
3. Quodbach, J., Preis, E., Karkossa, F., Winck, J., Finke, J.H., and Steiner, D. (2025). Novel Strategies for the Formulation of Poorly Water-Soluble Drug Substances by Different Physical Modification Strategies with a Focus on Peroral Applications. Pharmaceuticals, 18.10.3390/ph18081089 ↗
4. Innovative Medicinal Chemistry Strategies for Enhancing Drug Solubility10.1016/j.ejmech.2024.116842 ↗
5. Preparation and Evaluation of a Self-Emulsifying Drug Delivery System for Improving the Solubility and Permeability of Ticagrelor10.1021/acsomega.3c08700 ↗
6. API Solubility in Semi-Crystalline Polymer: Kinetic and Thermodynamic Phase Behavior of PVA-Based Solid Dispersions10.1016/j.ijpharm.2022.121855 ↗
7. Emerging Role of Biopharmaceutical Classification and Biopharmaceutical Drug Disposition System in Dosage Form Development: A Systematic Review10.4274/tjps.galenos.2021.73554 ↗
8. Potentiometric CheqSol and Standardized Shake-Flask Solubility Methods Are Complimentary Tools in Physicochemical Profiling10.1016/j.ejps.2020.105305 ↗
9. Pharmaceutical Amorphous Solid Dispersion: A Review of Manufacturing Strategies10.1016/j.apsb.2021.05.014 ↗
10. A Novel Amorphous Solid Dispersion Based on Drug–Polymer Complexation10.1007/s13346-020-00869-3 ↗
11. Cocrystals of Tuberculosis Antibiotics: Challenges and Missed Opportunities10.1016/j.ijpharm.2022.121924 ↗
12. Pharmaceutical Cocrystal of Antibiotic Drugs: A Comprehensive Review10.1016/j.heliyon.2022.e11872 ↗
13. Musuc, A.M. (2024). Cyclodextrins: Advances in Chemistry, Toxicology, and Multifaceted Applications. Molecules, 29.10.3390/molecules29225319 ↗
14. Cyclodextrins as an Encapsulation Molecular Strategy for Volatile Organic Compounds—Pharmaceutical Applications10.1016/j.colsurfb.2022.112758 ↗
15. Development of High-Drug-Loading Nanoparticles10.1002/cplu.202000496 ↗
16. Polymeric Nanofibers for Drug Delivery Applications: A Recent Review10.1007/s10856-022-06700-4 ↗
17. Nanoemulsion: An Emerging Novel Technology for Improving the Bioavailability of Drugs10.1155/2023/6640103 ↗
18. Solid Lipid Nanoparticles for Hydrophilic Drugs10.1016/j.jconrel.2021.05.032 ↗
19. Self-Emulsifying Drug Delivery System Improve Oral Bioavailability: Role of Excipients and Physico-Chemical Characterization10.2174/2211738508666200811104240 ↗
20. Pharmaceutical Cocrystal Drug Products: An Outlook on Product Development10.1016/j.tips.2018.10.006 ↗
21. Charge Converting Nanostructured Lipid Carriers Containing a Cell-Penetrating Peptide for Enhanced Cellular Uptake10.1016/j.jcis.2022.07.160 ↗
22. Development, Characterization, and Optimization of a Novel Abiraterone Acetate Formulation to Improve Biopharmaceutical Attributes Aided by Pharmacokinetic Modelling10.1208/s12249-021-02168-7 ↗
23. The Global Need for Effective Antibiotics: Challenges and Recent Advances10.1016/j.tips.2010.08.002 ↗
24. Emerging Health Risks of Pharmaceutical Pollutants in Water Sources: Public Health Perspectives and Policy Recommendations10.59783/aire.2025.73 ↗
25. Enhancing the Pharmacokinetics of Abiraterone Acetate through Lipid-Based Formulations: Addressing Solubility and Food Effect Challenges10.1007/s13346-024-01755-y ↗
26. Solubility and Bioavailability Improvement of Pazopanib Hydrochloride10.1016/j.ijpharm.2018.04.037 ↗
27. Strategies for Solubility Enhancement of Anthelmintics (Review)10.1007/s11094-020-02229-4 ↗
28. Amorphous Formulations for Dissolution and Bioavailability Enhancement of Poorly Soluble APIs10.1016/j.powtec.2015.05.012 ↗
29. Alhamhoom, Y., Kumaraswamy, T., Kumar, A., Nanjappa, S.H., Prakash, S.S., Rahamathulla, M., Thajudeen, K.Y., Ahmed, M.M., and Shivanandappa, T.B. (2024). Formulation and Evaluation of pH-Modulated Amorphous Solid Dispersion-Based Orodispersible Tablets of Cefdinir. Pharmaceutics, 16.10.3390/pharmaceutics16070866 ↗
30. Nanographene Oxide for Enhanced Dissolution Rate and Antibacterial Activity of Cefdinir10.1016/j.jddst.2021.102411 ↗
31. Cho, H.-J., Jee, J.-P., Kang, J.-Y., Shin, D.-Y., Choi, H.-G., Maeng, H.-J., and Cho, K. (2017). Cefdinir Solid Dispersion Composed of Hydrophilic Polymers with Enhanced Solubility, Dissolution, and Bioavailability in Rats. Molecules, 22.10.3390/molecules22020280 ↗
32. Formulation and Optimization of Surfactant-Modified Chitosan Nanoparticles Loaded with Cefdinir for Novel Topical Drug Delivery: Elevating Wound Healing Efficacy with Enhanced Antibacterial Properties10.1016/j.ijpharm.2024.124763 ↗
33. Absolute Bioavailability of Cefixime in Man10.1002/j.1552-4604.1988.tb03203.x ↗
34. Preparation, Characterization and Evaluation of Cefixime Ternary Inclusion Complexes Formated by Mechanochemical Strategy10.1007/s10847-023-01214-0 ↗
35. Ramos, V.C., Reyes, C.B.G., García, G.M., Quesada, M.I.S., Barrero, F.J.M.-C., Rábago, J.J.S., and Polo, M.S. (2022). ZIF-8 and Its Magnetic Functionalization as Vehicle for the Transport and Release of Ciprofloxacin. Pharmaceutics, 14.10.3390/pharmaceutics14112546 ↗
36. Chitosan-Induced Synergy for Extended Antimicrobial Potency and Enhanced In Vitro Drug Release of Free Base Ciprofloxacin Nanoplexes10.2174/2211738507666191021102256 ↗
37. Development, Characterization and Stability Evaluation of Ciprofloxacin-Loaded Parenteral Nutrition Nanoemulsions10.1080/10837450.2020.1720237 ↗
38. Fabrication and in Vitro Characterization of Delafloxacin-Laden Electrosprayed Hydroxypropyl Cellulose Nanoparticulated Solid Dispersions for Enhanced Aqueous Solubility and Release Rate of the Drug10.1080/00914037.2023.2289521 ↗
39. Anwer, M.K., Iqbal, M., Muharram, M.M., Mohammad, M., Ezzeldin, E., Aldawsari, M.F., Alalaiwe, A., and Imam, F. (2020). Development of Lipomer Nanoparticles for the Enhancement of Drug Release, Anti-Microbial Activity and Bioavailability of Delafloxacin. Pharmaceutics, 12.10.3390/pharmaceutics12030252 ↗
40. Clinical Pharmacokinetics and Pharmacodynamics of Delafloxacin10.1007/s13318-018-0520-8 ↗
41. Self Emulsifying Drug Delivery System: Norfloxacin Model Drug10.12688/f1000research.141057.1 ↗
42. Norfloxacin Delivery Systems Based on MCM-Type Silica Carriers Designed for the Treatment of Severe Infections10.1016/j.matchemphys.2019.121886 ↗
43. FormulationBCS: A Machine Learning Platform Based on Diverse Molecular Representations for Biopharmaceutical Classification System (BCS) Class Prediction10.1021/acs.molpharmaceut.4c00946 ↗
44. Solubility of Cefixime in Aqueous Mixtures of Deep Eutectic Solvents from Experimental Study and Modeling10.1016/j.molliq.2020.112636 ↗
45. Experimental and Thermodynamic Modeling of Cefixime Trihydrate Solubility in an Aqueous Deep Eutectic System10.1016/j.molliq.2020.112727 ↗
46. Incorporation of the Poorly Soluble Drug Cefixime inside the Micellar Core of Conventional and Gemini Surfactants10.1039/D2NJ00024E ↗
47. Sharma, M., Darwhekar, G.N., and Rathore, J. (2019, January 29–30). Chemical Modification of Ciprofloxacin IV Formulation to Combat Solubility and Stability Issues. Proceedings of the Emerging Interfaces of Physical Sciences and Technology, Ujjain, India.10.1063/5.0000579 ↗
48. Mechanochemical Synthesis, Thermoanalytical Study and Characterization of New Multicomponent Solid Forms of Norfloxacin with Saccharin10.1007/s10973-021-10658-w ↗
49. Norfloxacin Cocrystals: Mechanochemical Synthesis and Scale-up Viability Through Solubility Studies10.1016/j.xphs.2023.03.003 ↗
50. A Comparative Solubility Enhancement Study of Cefixime Trihydrate Using Different Dispersion Techniques10.1208/s12249-019-1395-y ↗
51. Dissolution Mechanisms of Amorphous Solid Dispersions: Role of Drug Load and Molecular Interactions10.1021/acs.molpharmaceut.2c00892 ↗
52. Cefdinir Inclusion in Mesoporous Silica as Effective Dissolution Enhancer with Improved Physical Stability10.29169/1927-5951.2021.11.10 ↗
53. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) (2024). Impurities: Guideline for Residual Solvents Q3C(R9), ICH Secretariat. Available online: https://database.ich.org/sites/default/files/ICH_Q3C(R9)_Guideline_MinorRevision_2024_2024_Approved.pdf.
54. Development and Characterization of Orodispersible Film Containing Cefixime Trihydrate10.1080/03639045.2020.1843477 ↗
55. Microdialysis and Nanofiltration Allow to Distinguish Molecularly Dissolved from Colloid-Associated Drug Concentrations during Biomimetic Dissolution Testing of Supersaturating Formulations10.1016/j.ejps.2022.106166 ↗
56. Conventional Methods and Future Trends in Antimicrobial Susceptibility Testing10.1016/j.sjbs.2023.103582 ↗
57. Oral Tablet Formulations Containing Cyclodextrin Complexes of Poorly Water Soluble Cefdinir to Enhance Its Bioavailability10.1016/j.jddst.2020.101742 ↗
58. Solubility Enhancement of Cefdinir using different Pharmaceutical Approaches for Enhancement of the Drug Performance
59. Rational Design of Natural Deep Eutectic Solvents Contributes to Desirable Shift of Ciprofloxacin in Biopharmaceutics Classification System10.1016/j.molliq.2024.126750 ↗
60. Assessment of the Utility of Chitosan Nanoparticles and Microfibers in Drug Delivery Applications of Sulfamethoxazole and Ciprofloxacin10.1039/D4NJ05421K ↗
61. Sikorski, D., Rosiak, P., Janczewski, Ł., Potrzebowski, M.J., Kregiel, D., Kaźmierski, S., Neubauer, D., Kolesińska, B., Frączyk, J., and Adamczyk, A. (2023). Synthesis and Characterization of Antibacterial Chitosan Films with Ciprofloxacin in Acidic Conditions. IJMS, 24.10.3390/ijms242015163 ↗
62. Khodir, W.K.W.A., Ismail, M.W., Hamid, S.A., Daik, R., Susanti, D., Taher, M., and Guarino, V. (2023). Synthesis and Characterization of Ciprofloxacin Loaded Star-Shaped Polycaprolactone–Polyethylene Glycol Hydrogels for Oral Delivery. Micromachines, 14.10.3390/mi14071382 ↗
63. Exploration of a W/O Nanoemulsion for Antibiofilm Activity against Cariogenic Enterococcus faecalis10.1021/acsomega.2c03180 ↗
64. Asghar, A.A., Akhlaq, M., Jalil, A., Azad, A.K., Asghar, J., Adeel, M., Albadrani, G.M., Al-Doaiss, A.A., Kamel, M., and Altyar, A.E. (2022). Formulation of Ciprofloxacin-Loaded Oral Self-Emulsifying Drug Delivery System to Improve the Pharmacokinetics and Antibacterial Activity. Front. Pharmacol., 13.10.3389/fphar.2022.967106 ↗
65. Holistic Study Design Following Quality by Design Approach for Fabrication of Hybrid Polymeric Nanoparticulate Based Dry Powders as Carriers for Ciprofloxacin10.1016/j.xphs.2024.04.017 ↗
66. Enhancement of Ciprofloxacin Activity by Incorporating It in Solid Lipid Nanoparticles10.4314/tjpr.v19i5.1 ↗
67. Coconut Oil and Shea Butter as Lipids for the Formulation of Ciprofloxacin-Loaded Nanoparticles10.1007/s12247-025-09922-5 ↗
68. Gomes, S.N., Biscaia, I.F.B., Lopes, D.S., Mengarda, M., Murakami, F.S., Oliveira, P.R., and Bernardi, L.S. (2023). Cocrystals Enhance Biopharmaceutical and Antimicrobial Properties of Norfloxacin. Pharmaceutics, 15.10.3390/pharmaceutics15092211 ↗
69. Effect of Commercial Nasal Steroid Preparation on Bacterial Growth10.1002/alr.22312 ↗
70. Thakur, V.K., and Thakur, M.K. (2015). Current State of the Potential Use of Chitosan as Pharmaceutical Excipient. Handbook of Polymers for Pharmaceutical Technologies, Wiley.
71. Nielsen, C.K., Kjems, J., Mygind, T., Snabe, T., and Meyer, R.L. (2016). Effects of Tween 80 on Growth and Biofilm Formation in Laboratory Media. Front. Microbiol., 7.10.3389/fmicb.2016.01878 ↗
72. Thermoreversible Gel Formulations Containing Sodium Lauryl Sulfate or n-Lauroylsarcosine as Potential Topical Microbicides against Sexually Transmitted Diseases10.1128/AAC.45.6.1671-1681.2001 ↗
73. Preparation and Ex-Vivo Evaluation of Stabilized Cefdinir Nanosuspension10.53350/pjmhs20221612789 ↗
74. Solubility Enhancementofcefixime Trihydrate by Solid Dispersions Using Hydrotropic Solubilization Technique and Their Characterization10.1590/s2175-97902020000118553 ↗
75. Spray Freeze Drying to Solidify Nanosuspension of Cefixime into Inhalable Microparticles10.1007/s40199-021-00426-4 ↗
76. Design and Development of Lipid Modified Arginine Based Self-Nanoemulsifying Drug Delivery Systems for Improved Antibacterial Activity of Cefixime against S. Aureus and E. Coli10.1016/j.molstruc.2023.136664 ↗
77. Fabrication of Novel Bio-Compatible Cefixime Nanoparticles Using Chitosan and Azadirachta Indica Fruit Mucilage as Natural Polymers10.1016/j.jddst.2021.102750 ↗
78. Lim, L.M., Park, J.-W., and Hadinoto, K. (2022). Benchmarking the Solubility Enhancement and Storage Stability of Amorphous Drug–Polyelectrolyte Nanoplex against Co-Amorphous Formulation of the Same Drug. Pharmaceutics, 14.10.3390/pharmaceutics14050979 ↗
79. A Portfolio of Ciprofloxacin Hydrochloride Ionic Cocrystals with Phenolic Acids for Tailoring Dissolution and Solubility10.1021/acs.cgd.4c01711 ↗
80. Uhljar, L.É., Kan, S.Y., Radacsi, N., Koutsos, V., Szabó-Révész, P., and Ambrus, R. (2021). In Vitro Drug Release, Permeability, and Structural Test of Ciprofloxacin-Loaded Nanofibers. Pharmaceutics, 13.10.3390/pharmaceutics13040556 ↗
81. Improved Antimicrobial Activity and Oral Bioavailability of Delafloxacin by Self-Nanoemulsifying Drug Delivery System (SNEDDS)10.1016/j.jddst.2021.102572 ↗
82. Fael, H., Barbas, R., Prohens, R., Ràfols, C., and Fuguet, E. (2021). Synthesis and Characterization of a New Norfloxacin/Resorcinol Cocrystal with Enhanced Solubility and Dissolution Profile. Pharmaceutics, 14.10.3390/pharmaceutics14010049 ↗
83. Sardaru, M.-C., Rosca, I., Morariu, S., Ursu, E.-L., and Rotaru, A. (2025). Synergistic Antibacterial Action of Norfloxacin-Encapsulated G4 Hydrogels: The Role of Boronic Acid and Cyclodextrin. Gels, 11.10.3390/gels11010035 ↗
84. Novel Interpenetrating Polymeric Network Based Microbeads for Delivery of Poorly Water Soluble Drug10.1007/s10965-020-02077-6 ↗
85. Cirri, M., Mennini, N., Nerli, G., Rubia, J., Casalone, E., Melani, F., Maestrelli, F., and Mura, P. (2021). Combined Use of Cyclodextrins and Amino Acids for the Development of Cefixime Oral Solutions for Pediatric Use. Pharmaceutics, 13.10.3390/pharmaceutics13111923 ↗
86. Mahmood, A., Khan, L., Ijaz, M., Nazir, I., Naseem, M., Tahir, M.A., Aamir, M.N., Rehman, M.U., and Asim, M.H. (2023). Enhanced Intestinal Permeability of Cefixime by Self-Emulsifying Drug Delivery System: In-Vitro and Ex-Vivo Characterization. Molecules, 28.10.3390/molecules28062827 ↗
87. Formulation and Evaluation of Quince Seeds Mucilage—Sodium Alginate Microspheres for Sustained Delivery of Cefixime and Its Toxicological Studies10.1016/j.arabjc.2022.103811 ↗
88. Abdelkader, A., Nallbati, L., and Keck, C.M. (2023). Improving the Bioactivity of Norfloxacin with Tablets Made from Paper. Pharmaceutics, 15.10.3390/pharmaceutics15020375 ↗
89. Abdelkader, A., Preis, E., and Keck, C.M. (2022). SmartFilm Tablets for Improved Oral Delivery of Poorly Soluble Drugs. Pharmaceutics, 14.10.3390/pharmaceutics14091918 ↗
90. Customized 3D-Printed Hollow Capsular Device Filled with Norfloxacin-Loaded Micropellets for Controlled-Release Delivery10.1007/s13346-022-01198-3 ↗
91. Surfactant Vesicles for Enhanced Antitoxoplasmic Effect of Norfloxacin: In Vitro and In Vivo Evaluations10.1016/j.ijpharm.2023.122912 ↗
92. Deep Eutectic Solvents Based on L-Arginine and 2-Hydroxypropyl-β-Cyclodextrin for Drug Carrier and Penetration Enhancement10.1208/s12249-023-02638-0 ↗
93. Study on the Structure, Solubilities, Antibacterial Activities and In Vivo Toxicity of Hesperetin and Norfloxacin Cocrystal10.1007/s11094-024-03205-y ↗
94. Development of Water-Soluble Nanoformulations of Novel Pyrazolone Derivatives and the Evaluation of Their Antibacterial and Antioxidant Activities10.1007/s12668-024-01675-8 ↗
95. Design, Synthesis, and Evaluation of Carbonate-Linked Halogenated Phenazine-Quinone Prodrugs with Improved Water-Solubility and Potent Antibacterial Profiles10.1021/acsinfecdis.2c00558 ↗
96. Esposito, A., D’Alonzo, D., D’Errico, S., De Gregorio, E., and Guaragna, A. (2020). Toward the Identification of Novel Antimicrobial Agents: One-Pot Synthesis of Lipophilic Conjugates of N-Alkyl d- and l-Iminosugars. Mar. Drugs, 18.10.3390/md18110572 ↗
97. Out of Control: The Need for Standardised Solvent Approaches and Data Reporting in Antibiofilm Assays Incorporating Dimethyl-Sulfoxide (DMSO)10.1016/j.bioflm.2022.100081 ↗
98. U.S. Food and Drug Administration (2026, June 01). Guidance for Industry: Applications Covered by Section 505(b)(2), Available online: https://www.fda.gov/media/72419/download.
99. European Parliament and Council of the European Union (2024). Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Use. Off. J. Eur. Communities L, 311, 1–66. Available online: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02001L0083-20220101.